Akers Biosciences said first-half revenue was ahead of its own expectations after it capitalised on demand for its disposable breath alcohol detectors.In a trading update, Akers said it had delivered 4.9m of the detectors to its global partner, Chubeworkx. The Chube-branded detectors are certified by France's national reference laboratory for use in cars under a new law that requires French motorists to fit breath alcohol detectors in their cars.The product is also licensed in Australia and accepted in New Zealand and South Africa. Akers agreed in June to supply Chubeworkx in the US.Thomas Nicolette, Chief Executive of Akers, said: "We are pleased to inform our shareholders of [Akers'] substantial commercial progress thus far in 2013. The distribution relationships we have forged internationally and in the United States have proven to be extremely productive from the perspectives of financial performance and market penetration. "We are keenly focused on accelerating the sales growth of our current product offerings and excited to complete the commercialisation of our emerging rapid diagnostic devices for launch into attractive, sizeable markets."SF